Putting you in control of von Willebrand disease

wilate® is a VWF/FVIII concentrate that is proven to be effective in people with all types of von Willebrand disease for the management of bleeding during surgery, as prophylaxis for the prevention of bleeding, and for on-demand treatment of bleeds¹⁻³

Quick links

SmPC
wilate dosing
Patient information

wilate® is a high-purity plasma-derived von Willebrand factor and coagulation factor VIII (VWF/FVIII) concentrate

wilate® was developed specifically for people with von Willebrand disease (VWD), and contains VWF and FVIII in a physiological 1:1 activity ratio, which may facilitate simple dosing and monitoring even when repeated dosing is needed.4, 5

The purification process includes two virus inactivation steps in order to ensure a high-purity product free of viral contamination.4

Over 15 years of clinical and real-life experience have proven the efficacy and tolerability of wilate® in people with all types of von Willebrand disease for surgery, on-demand treatment and prophylaxis.1-3

*Based on von Willebrand factor and factor VIII activity levels. FVIII, coagulation factor VIII; VWF, von Willebrand factor.

In the European Union, wilate® is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease, when desmopressin treatment alone is ineffective or contra-indicated6

Physiological 1:1 ratio of VWF and FVIII in wilate®

One of the functions of VWF is to bind to and protect FVIII from proteolytic degradation.4

As a result, people with von Willebrand disease may have low levels of both VWF and FVIII, both of which need to be corrected in order to restore normal haemostasis.4

wilate® contains VWF and FVIII in a balanced 1:1 ratio*, which is similar to the activity ratio of VWF and FVIII in the plasma of healthy individuals.4

*Based on von Willebrand factor and factor VIII activity levels.

The balanced ratio of VWF and FVIII* may simplify dosing and monitoring of wilate®2

*Based on von Willebrand factor and factor VIII activity levels.

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII concentrate

wilate® is made from pooled human plasma that has been collected in GMP-compliant donation centres, which are regularly inspected by Octapharma and national and international authorities9

FVIII, factor VIII; GMP, good manufacturing practice; VWF, von Willebrand factor.

All individual plasma samples undergo extensive testing for viruses, including for HIV, hepatitis A, B and C and parvovirus B199, 10

FVIII, factor VIII; HIV, human immunodeficiency virus; von Willebrand factor.

wilate® is purified through a series of carefully controlled processing steps, all designed to minimise impurities and ensure viral safety4

Two chromatographic steps ensure high purity and remove non-essential proteins4

Viral safety is achieved by two complementary virus inactivation steps4

Manufacturing of wilate®

Double virus inactivation process

HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

Manufacturing of wilate®

wilate® is a high-purity, human VWF/FVIII concentrate

The manufacturing process of wilate® preserves the structure and multimer distribution of VWF seen in the plasma of healthy individuals4

Figure adapted from Windyga et al. 2011
SHP, standard human plasma

References

  1. Srivastava A et al. Haemophilia 2017; 23:264-72.
  2. Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072-9.
  3. Berntorp E and Windyga J. Haemophilia 2009; 15:122-30.
  4. Stadler M et al. Biologicals 2006; 34:281-8.
  5. Kessler CM et al. Thromb Haemost 2011; 106:279-88.
  6. wilate® SmPC, updated June 2021.
  7. Sholzberg M et al. TH Open 2021; 5:e264-72.
  8. Octapharma AG, data on file.
  9. octapharma.com/products/quality-and-safety; last accessed July 2021.
  10. octapharma.com/products/production-process; last accessed July 2021.
  11. Biesert L and Suhartano H. Vox Sang 1998; 74(Suppl.1):207-12.
  12. Teitel JM. Ann Med 2000; 32:485-92.